��������

Hao Hong started Asymchem with a single laboratory in North Carolina’s Research Triangle Park (RTP), he did it with not much more than his unbridled enthusiasm for chemistry. Fortunately, this period of steadfast faith in therapeutics coincided with the budding Chinese CDMO industry. In 2000, through careful consideration and investment, Asymchem extended its fast-growing operations to China and the story began to unfold.

Today Asymchem employs more than 5500 people at eight sites and counts the clients as the world’s top pharmaceutical companies. While I’m proud of such a significant accomplishment, the numerous advances in novel technology including the commercial-sized application of flow chemistry in API manufacturing, have fueled his continued passion for chemistry. Along with the recent construction of Asymchem’s multidimensional service platform, they’ve realized that the enriched expertise and commitment to innovation can extend beyond “big pharma” to those newly emerged biotech labs and even smaller-sized specialty pharmaceutical companies adopting cutting-edge therapeutics. Using the “Know How” spirit, Asymchem has made it its mission to help these innovators successfully bring their products to market.